Solution structure, conformational dynamics, and CD4-induced activation in full-length, glycosylated, monomeric HIV gp120

Journal of Virology

Volumn 86, Issue 16, 2012, Pages 8750-8764

  Guttman, Miklos ^a   Kahn, Maria ^a   Garcia, Natalie K ^a   Hu, Shiu Lok ^a   Lee, Kelly K ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DEUTERIUM; GLYCOPROTEIN GP 120; HYDROGEN;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DEUTERIUM HYDROGEN EXCHANGE; EMBRYO; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; MOLECULAR IMAGING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING; X RAY CRYSTALLOGRAPHY;

ANTIGENS, CD4; GLYCOPROTEINS; HIV ENVELOPE PROTEIN GP120; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN CONFORMATION; SCATTERING, SMALL ANGLE;

EID: 84865066445     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.07224-11     Document Type: Article

References (83)

1. Ashish, Garg R, Anguita J, Krueger JK. 2006. Binding of full-length HIV-1 gp120 to CD4 induces structural reorientation around the gp120 core. Biophys. J. 91:L69 -L71.
2. Bai Y, Milne JS, Mayne L, Englander SW. 1993. Primary structure effects on peptide group hydrogen exchange. Proteins 17:75-86.
3. Beddows S, Lister S, Cheingsong R, Bruck C, Weber J. 1999. Comparison of the antibody repertoire generated in healthy volunteers following immunization with a monomeric recombinant gp120 construct derived from a CCR5/CXCR4-using human immunodeficiency virus type 1 isolate with sera from naturally infected individuals. J. Virol. 73:1740-1745.
4. Bures R, et al. 2000. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 16:2019-2035.
5. Center RJ, Earl PL, Lebowitz J, Schuck P, Moss B. 2000. The human immunodeficiency virus type 1 gp120 V2 domain mediates gp41-independent intersubunit contacts. J. Virol. 74:4448-4455.
6. Chen B, et al. 2005. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841.
7. DeLano WL. 2002. The PyMOL molecular graphics system. DeLano Scientific, San Carlos, CA.
8. Dey B, et al. 2007. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J. Virol. 81: 5579-5593.
9. Dey B, et al. 2009. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog. 5:e1000445. doi:10.1371/journal.ppat.1000445.
10. Diskin R, Marcovecchio PM, Bjorkman PJ. 2010. Structure of a clade CHIV-1 gp120 bound to CD4 and CD4-induced antibody reveals anti-CD4 polyreactivity. Nat. Struct. Mol. Biol. 17:608-613.
11. Eswar N, et al. 2006. Comparative protein structure modeling using Modeller. Curr. Protoc. Bioinformatics 5:Unit 5.6.
12. Falkowska E, et al. 2012. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86:4394-4403.
13. Finzi A, et al. 2010. Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J. Virol. Methods 168:155-161.
14. Finzi A, et al. 2010. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol. Cell 37:656-667.
15. Fischer H, de Oliveira Neto M, Napolitano HB, Craievich AF, Polikarpov I. 2010. Determination of the molecular weight of proteins in solution from a single small-angle X-ray scattering measurement on a relative scale. J. Appl. Crystallogr. 43:101-109.
16. Guvench O, et al. 2008. Additive empirical force field for hexopyranose monosaccharides. J. Comput. Chem. 29:2543-2564.
17. Guvench O, Hatcher ER, Venable RM, Pastor RW, Mackerell AD. 2009. CHARMM additive all-atom force field for glycosidic linkages between hexopyranoses. J. Chem. Theory Comput. 5:2353-2370.
18. Hansen JE, Clausen H, Hu SL, Nielsen JO, Olofsson S. 1992. An O-linked carbohydrate neutralization epitope of HIV-1 gp 120 is expressed by HIV-1 env gene recombinant vaccinia virus. Arch. Virol. 126: 11-20.
19. Harris A, et al. 2011. Trimeric HIV-1 glycoprotein gp140 immunogens and native HIV-1 envelope glycoproteins display the same closed and open quaternary molecular architectures. Proc. Natl. Acad. Sci. U. S. A. 108:11440-11445.
20. Hoxie JA. 2010. Toward an antibody-based HIV-1 vaccine. Annu. Rev. Med. 61:135-152.
21. Hu SL, Stamatatos L. 2007. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5:507-513.
22. Huang CC, et al. 2005. Structure of a V3-containing HIV-1 gp120 core. Science 310:1025-1028.
23. Huang CC, et al. 2004. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gp120. Proc. Natl. Acad. Sci. U. S. A. 101:2706-2711.
24. Humbert M, et al. 2008. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One 3:e3937. doi:10.1371/ journal.pone.0003937.
25. Koch M, et al. 2003. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313:387-400.
26. Kong L, et al. 2010. Local conformational stability of HIV-1 gp120 in unliganded and CD4-bound states as defined by amide hydrogen/ deuterium exchange. J. Virol. 84:10311-10321.
27. Kozin MB, Svergun DI. 2001. Automated matching of high- and lowresolution structural models. J. Appl. Crystallogr. 34:33-41.
28. Kwon YD, et al. 2012. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc. Natl. Acad. Sci. U. S. A. 109:5663-5668.
29. Kwong PD, et al. 2002. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
30. Kwong PD, et al. 1998. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
31. Leonard CK, et al. 1990. Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
32. Lewis MS, Junghans RP. 2000. Ultracentrifugal analysis of molecular mass of glycoproteins of unknown or ill-defined carbohydrate composition. Methods Enzymol. 321:136-149.
33. Li Y, et al. 2011. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J. Virol. 85:8954-8967.
34. Lisal J, et al. 2005. Functional visualization of viral molecular motor by hydrogen-deuterium exchange reveals transient states. Nat. Struct. Mol. Biol. 12:460-466.
35. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455:109-113.
36. Liu L, Cimbro R, Lusso P, Berger EA. 2011. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc. Natl. Acad. Sci. U. S. A. 108:20148-20153.
37. Lusso P, et al. 2005. Cryptic nature of a conserved, CD4-inducible V3 loop neutralization epitope in the native envelope glycoprotein oligomer of CCR5-restricted, but not CXCR4-using, primary human immunodeficiency virus type 1 strains. J. Virol. 79:6957-6968.
38. Mascola JR, et al. 1996. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J. Infect. Dis. 173:340-348.
39. McLellan JS, et al. 2011. Structure of HIV-1 gp120V1/V2 domain with broadly neutralizing antibody PG9. Nature 480:336-343.
40. Medzihradszky KF, Burlingame AL. 2005. Characterization of protein N-glycosylation. Methods Enzymol. 405:116-138.
41. Morgan CR, Engen JR. 2009. Investigating solution-phase protein structure and dynamics by hydrogen exchange mass spectrometry. Curr. Protoc. Protein Sci. 17:Unit 17.16.11-17.
42. Mylonas E, Svergun DI. 2007. Accuracy of molecular mass determination of proteins in solution by small-angle X-ray scattering. J. Appl. Crystallogr. 40:s245-s249.
43. Myszka DG, et al. 2000. Energetics of the HIV gp120-CD4 binding reaction. Proc. Natl. Acad. Sci. U. S. A. 97:9026-9031.
44. Pancera M, et al. 2010. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc. Natl. Acad. Sci. U. S. A. 107:1166-1171.
45. Pantophlet R, Burton DR. 2006. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769.
46. Pelikan M, Hura GL, Hammel M. 2009. Structure and flexibility within proteins as identified through small angle X-ray scattering. Gen. Physiol. Biophys. 28:174-189.
47. Petoukhov MV, Konarev PV, Kikhney AG, Svergun DI. 2007. ATSAS 2.1: towards automated and web-supported small-angle scattering data analysis. J. Appl. Crystallogr. 40:s223-s228.
48. Petoukhov MV, Svergun DI. 2007. Analysis of X-ray and neutron scattering from biomolecular solutions. Curr. Opin. Struct. Biol. 17:562-571.
49. Pettersen EF, et al. 2004. UCSF Chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612.
50. Putnam CD, Hammel M, Hura GL, Tainer JA. 2007. X-ray solution scattering (SAXS) combined with crystallography and computation: defining accurate macromolecular structures, conformations and assemblies in solution. Q. Rev. Biophys. 40:191-285.
51. Raska M, et al. 2010. Glycosylation patterns of HIV-1 gp120 depend on the type of expressing cells and affect antibody recognition. J. Biol. Chem. 285:20860-20869.
52. Rerks-Ngarm S, et al. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361:2209-2220.
53. Rizzuto CD, et al. 1998. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 280:1949-1953.
54. Rusert P, et al. 2011. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against crossneutralizing antibodies. J. Exp. Med. 208:1419-1433.
55. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
56. Scandella CJ, et al. 1993. Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development. AIDS Res. Hum. Retroviruses 9:1233-1244.
57. Scanlan CN, Offer J, Zitzmann N, Dwek RA. 2007. Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446:1038-1045.
58. Scheid JF, et al. 2011. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333:1633-1637.
59. Schneidman-Duhovny D, Hammel M, Sali A. 2010. FoXS: a web server for rapid computation and fitting of SAXS profiles. Nucleic Acids Res. 38:W540-W544.
60. Smirnovas V, et al. 2009. Distinct structures of scrapie prion protein (PrPSc)-seeded versus spontaneous recombinant prion protein fibrils re-vealed by hydrogen/deuterium exchange. J. Biol. Chem. 284:24233-24241.
61. Smith DL, Deng Y, Zhang Z. 1997. Probing the non-covalent structure of proteins by amide hydrogen exchange and mass spectrometry. J. Mass Spectrom. 32:135-146.
62. Smolsky IL, et al. 2007. Biological small-angle X-ray scattering facility at the Stanford Synchrotron Radiation Laboratory. J. Appl. Crystallogr. 40: s453-s458.
63. Sullivan N, et al. 1998. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies. J. Virol. 72:6332-6338.
64. Sullivan N, et al. 1998. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization. J. Virol. 72:4694-4703.
65. Svergun DI. 1992. Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Crystallogr. 25:495-503.
66. Svergun DI. 1991. Mathematical methods in small-angle scattering data analysis. J. Appl. Crystallogr. 24:485-492.
67. Svergun DI. 1999. Restoring low resolution structure of biological macromolecules from solution scattering using simulated annealing. Biophys. J. 76:2879-2886.
68. Svergun DI, Petoukhov MV, Koch MH. 2001. Determination of domain structure of proteins from X-ray solution scattering. Biophys. J. 80:2946-2953.
69. Volkov VV, Svergun DI. 2003. Uniqueness of ab-initio shape determination in small-angle scattering. J. Appl. Crystallogr. 36:860-864.
70. Vranken WF, Budesinsky M, Fant F, Boulez K, Borremans FA. 1995. The complete consensus V3 loop peptide of the envelope protein gp120 of HIV-1 shows pronounced helical character in solution. FEBS Lett. 374: 117-121.
71. Weis DD, Engen JR, Kass IJ. 2006. Semi-automated data processing of hydrogen exchange mass spectra using HX-Express. J. Am. Soc. Mass Spectrom. 17:1700-1703.
72. Weis DD, Wales TE, Engen JR, Hotchko M, Ten Eyck LF. 2006. Identification and characterization of EX1 kinetics in H/D exchange mass spectrometry by peak width analysis. J. Am. Soc. Mass Spectrom. 17: 1498-1509.
73. White TA, et al. 2010. Molecular architectures of trimeric SIV and HIV-1 envelope glycoproteins on intact viruses: strain-dependent variation in quaternary structure. PLoS Pathog. 6:e1001249. doi:10.1371/ journal.ppat.1001249.
74. Wriggers W, Birmanns S. 2001. Using situs for flexible and rigid-body fitting of multiresolution single-molecule data. J. Struct. Biol. 133:193-202.
75. Wu SR, et al. 2010. Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure. Proc. Natl. Acad. Sci. U. S. A. 107:18844-18849.
76. Wu X, et al. 2010. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329:856-861.
77. Wyatt R, et al. 1995. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J. Virol. 69:5723-5733.
78. Zanetti G, Briggs JA, Grunewald K, Sattentau QJ, Fuller SD. 2006. Cryo-electron tomographic structure of an immunodeficiency virus envelope complex in situ. PLoS Pathog. 2:e83. doi:10.1371/ journal.ppat.0020083.
79. Zhang Z, Post CB, Smith DL. 1996. Amide hydrogen exchange determined by mass spectrometry: application to rabbit muscle aldolase. Biochemistry 35:779-791.
80. Zhou T, et al. 2010. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329:811-817.
81. Zhou T, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
82. Zhu P, et al. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852.
83. Zwick MB, et al. 2003. A novel human antibody against human immunodeficiency virus type 1 gp120 is V1, V2, and V3 loop dependent and helps delimit the epitope of the broadly neutralizing antibody immunoglobulin G1 b12. J. Virol. 77:6965-6978.